Meridian Bioscience

Meridian Bioscience is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Our products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori, foodborne diseases and respiratory infections.
In addition, we develop and manufacture a variety of biological and non-biological materials used in proficiency testing programs.

Cincinnati, US
Size (employees)
650 (est)+13%
Meridian Bioscience was founded in 1977 and is headquartered in Cincinnati, US

Meridian Bioscience Office Locations

Meridian Bioscience has an office in Cincinnati
Cincinnati, US (HQ)
3471 River Hills Dr

Meridian Bioscience Metrics

Meridian Bioscience Financial Metrics

Revenue (2016)

$196.1 m

Revenue growth (2015-16), %


Gross profit

$127.8 m

Gross profit margin (2016), %


Net income (2016)

$32.2 m

Market capitalization (21-Mar-2017)

$555 m

Closing share price (21-Mar-2017)


Cash (30-Sep-2016)

$47.2 m
Meridian Bioscience's current market capitalization is $555 m.
Meridian Bioscience's revenue was reported to be $196.1 m in 2016 which is a 0.6% increase from the previous period.
Y, 2013Y, 2014Y, 2015Y, 2016


$188.7 m$188.8 m$194.8 m$196.1 m

Revenue growth, %


Cost of goods sold

$67.6 m$71.6 m$72.9 m$68.3 m

Gross profit

$121 m$117.2 m$121.9 m$127.8 m

Gross profit Margin, %


Operating expense total

$63.7 m$64.9 m$65.8 m$76.4 m


$57.3 m$52.4 m$56.1 m$51.4 m

EBIT margin, %


Interest expense

$897 k

Interest income

$44 k$25 k$23 k$67 k

Pre tax profit

$57.4 m$52.1 m$55.1 m$50.6 m

Income tax expense

$19.3 m$17.4 m$19.5 m$18.4 m

Net Income

$38 m$34.7 m$35.5 m$32.2 m
FY, 2013FY, 2014FY, 2015FY, 2016


$44.3 m$43 m$50 m$47.2 m

Accounts Receivable


$34.8 m$35.5 m$35.8 m$45.1 m

Current Assets

$114.1 m$112.7 m$122.9 m$126.8 m


$23.1 m$23.2 m$22.3 m$62 m

Total Assets

$176.7 m$176.9 m$183.3 m$251.8 m

Accounts Payable

$5.6 m$5 m$6.6 m$7.6 m

Total Debt

$58.4 m

Current Liabilities

$21.7 m$13.7 m$15.3 m$22.6 m

Non-Current Liabilities

$2.2 m$2.2 m$62.8 m

Total Liabilities

$15.9 m$17.4 m$85.4 m

Additional Paid-in Capital

$107.4 m$111.9 m$117.2 m$122.4 m

Retained Earnings

$46.9 m$48.9 m$51.1 m$49.6 m

Total Equity

$155 m$161 m$165.9 m$166.5 m

Debt to Equity Ratio

0.4 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.1 x1.1 x1.1 x1.5 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

$38 m$34.7 m$35.5 m$32.2 m

Accounts Receivable


Accounts Payable

Cash From Operating Activities

$44.4 m$38.3 m$42.8 m$37.2 m

Purchases of PP&E

($3.2 m)($5.3 m)($4.6 m)($4 m)

Cash From Investing Activities

($3.3 m)($7 m)($3.6 m)($66.7 m)

Dividends Paid

($31.4 m)($32.8 m)($33.4 m)($33.6 m)

Interest Paid

$879 k

Income Taxes Paid

$20.1 m$20 m$20.2 m$17.9 m

Meridian Bioscience Market Value History

Meridian Bioscience Online Presence

Meridian Bioscience Company Life

You may also be interested in